HomeRLF • SWX
add
RELIEF THERAPEUTICS Holding SA
Previous close
CHF 1.17
Day range
CHF 1.17 - CHF 1.29
Year range
CHF 1.17 - CHF 15.00
Market cap
17.90M CHF
Avg Volume
16.67K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
| (CHF) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.65M | 16.41% |
Operating expense | 5.19M | -39.77% |
Net income | -20.84M | -71.60% |
Net profit margin | -1.26K | -47.41% |
Earnings per share | — | — |
EBITDA | -3.05M | 54.28% |
Effective tax rate | 12.33% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 14.56M | -24.33% |
Total assets | 76.39M | -59.54% |
Total liabilities | 24.16M | -44.30% |
Total equity | 52.23M | — |
Shares outstanding | 12.42M | — |
Price to book | 0.28 | — |
Return on assets | -12.98% | — |
Return on capital | -17.97% | — |
Cash Flow
Net change in cash
| (CHF) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -20.84M | -71.60% |
Cash from operations | -3.57M | 23.94% |
Cash from investing | 4.46M | 375.58% |
Cash from financing | -62.00K | -107.07% |
Net change in cash | 882.00K | 116.59% |
Free cash flow | 2.19M | 162.23% |
About
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Founded
2013
Website
Employees
64
